N
KYTX icon

Nuveen’s Kyverna Therapeutics KYTX Stock Holding History

Nuveen’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,508
Closed -$91.7K – 3432
2025
Q1 		$91.7K Buy
47,508
+24,660
+108% +$72.9K ﹤0.01% 3224
2024
Q4 		$85.5K Hold
22,848
– – ﹤0.01% 3299
2024
Q3 		$112K Hold
22,848
– – ﹤0.01% 3299
2024
Q2 		$171K Buy
+22,848
New +$349K ﹤0.01% 3245

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen's KYTX Position: Q2 2025 in Review

Nuveen sold out of Kyverna Therapeutics (KYTX) in Q2 2025, closing a stake of 47,508 shares — an estimated $91.7K sold.

Nuveen first reported a position in KYTX in Q2 2024 and held it in 4 quarters. The position peaked at $171K in Q2 2024. 79 funds tracked by Wall St. Rank hold KYTX as of Q2 2025.

  • Nuveen reported no remaining Kyverna Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 47,508 Kyverna Therapeutics shares in Q2 2025, an estimated $91.7K.
  • Nuveen first reported a position in Kyverna Therapeutics in Q2 2024 and held it in 4 quarters.
  • Nuveen's Kyverna Therapeutics position peaked at $171K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.